title: Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity.
abstract: Human hexokinase (HK) II, a glucose phosphorylating enzyme in muscle tissue, plays a central role in glucose metabolism. Since reduced insulin-stimulated glucose uptake and reduced glucose-6-phosphate content in muscle have been demonstrated in pre-non-insulin-dependent diabetes mellitus (pre-NIDDM) and NIDDM subjects, we have examined the coding region of the HKII gene in NIDDM patients to determine whether these patients show genetic polymorphisms that are associated with or contribute to the disease. Single-strand conformational polymorphism analysis and nucleotide sequencing were initially performed on the entire coding region of the HKII gene of 38 insulin-resistant NIDDM patients and 5 healthy control subjects. This analysis revealed four missense mutations at codons 142 (Gln to His), 148 (Leu to Phe), 497 (Arg to Gln), and 844 (Arg to Lys) and an additional six exon polymorphisms that did not predict any change in amino acid composition of the protein. One homozygous and nine heterozygous carriers of the codon 142 mutation were found among the NIDDM patients. The mutations at codons 148, 497, and 844 were each found in one diabetic subject and only on one allele. There were no carriers of compound heterozygous mutations. A subsequent study of 301 patients with NIDDM and 151 healthy control subjects revealed no additional mutations at codons 148, 497, or 844. The total frequency of the mutated allele at codon 142 was 18.9% among the control subjects and 17.0% among the NIDDM patients (chi 2 = 0.56, P = 0.45).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: S M
authors.initials: SM
authors.lastname: Echwald
authors.forename: C
authors.initials: C
authors.lastname: Bjørbaek
authors.forename: T
authors.initials: T
authors.lastname: Hansen
authors.forename: J O
authors.initials: JO
authors.lastname: Clausen
authors.forename: H
authors.initials: H
authors.lastname: Vestergaard
authors.forename: J R
authors.initials: JR
authors.lastname: Zierath
authors.forename: R L
authors.initials: RL
authors.lastname: Printz
authors.forename: D K
authors.initials: DK
authors.lastname: Granner
authors.forename: O
authors.initials: O
authors.lastname: Pedersen
mesh_terms: D000328:Adult; D000483:Alleles; D000595:Amino Acid Sequence; D000886:Anthropometry; D001483:Base Sequence; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015992:Body Mass Index; D003062:Codon / Q000235:genetics; D017931:DNA Primers; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology; D005091:Exons; D006580:Genetic Carrier Screening; D005951:Glucose Tolerance Test; D006593:Hexokinase / Q000235:genetics*; D006720:Homozygote; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D008969:Molecular Sequence Data; D010809:Physical Fitness; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011230:Precancerous Conditions / Q000235:genetics; D012016:Reference Values; D015183:Restriction Mapping; D014044:Tolbutamide / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D003062:Codon; D017931:DNA Primers; D007328:Insulin; D014044:Tolbutamide; D006593:Hexokinase